The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?

Future Microbiology
Cornelis H van Werkhoven, Marc Jm Bonten

Abstract

Pneumococcal community-acquired pneumonia (PCAP) and invasive pneumococcal disease (IPD) are important causes of morbidity and mortality in elderly. In the Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA), a randomized double-blind placebo-controlled trial of 84,496 community-dwelling immunocompetent adults over 65 years of age, the 13-valent pneumococcal conjugate vaccine (PCV13) reduced the incidence of first episode of vaccine-type (VT) PCAP with 38 and of VT-IPD with 76% in the modified intention-to-treat population. In The Netherlands, where PCV7 immunization of newborns was introduced in 2007 and replaced by PCV10 in 2011, introduction of PCV13 immunization of elderly--based on 2012 data--would be highly cost effective. However, this is probably different in countries where the VT disease burden has declined more, for instance due to herd effects following child immunization with PCV13. Apart from cost-effectiveness analyses, ethical aspects of PCAP prevention should be taken into account in policy making for pneumococcal vaccination in elderly.

References

Feb 19, 2002·International Journal of Antimicrobial Agents·Helena K Parsons, David H Dockrell
Mar 19, 2002·American Journal of Respiratory and Critical Care Medicine·Vladimir KaplanWalter T Linde-Zwirble
Jan 28, 2004·Archives of Internal Medicine·Jenny T van der SteenGerrit van der Wal
Jan 7, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Anke HussMatthias Egger
Jul 1, 2009·Pediatrics·Susan S HuangJonathan A Finkelstein
May 9, 2012·The Journal of Medicine and Philosophy·Anya Plutynski
Nov 3, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Menno R van den BerghElisabeth A M Sanders
Feb 12, 2013·The European Respiratory Journal·Susanne M HuijtsMarc J M Bonten
Feb 22, 2013·Current Opinion in Infectious Diseases·Marcos I RestrepoAntonio Anzueto
Mar 20, 2013·Geriatrics & Gerontology International·Yohei OshitaniHirotoshi Matsui
Dec 18, 2013·The Pediatric Infectious Disease Journal·Katherine E Fleming-DutraKatherine L O'Brien
Feb 18, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A TorresT Welte
Mar 19, 2015·The New England Journal of Medicine·Marc J M BontenDiederick E Grobbee
Jul 15, 2015·The European Respiratory Journal·Marie-Josée J MangenG Ardine de Wit

❮ Previous
Next ❯

Citations

May 14, 2016·Vaccine·Cornelis H van WerkhovenMarc J M Bonten
Sep 30, 2016·Frontiers in Immunology·Ger T Rijkers
Dec 29, 2016·International Journal of Molecular Sciences·Nicola Principi, Susanna Esposito
Nov 19, 2017·Respirology : Official Journal of the Asian Pacific Society of Respirology·Jane Hadfield, Lesley Bennett

❮ Previous
Next ❯

Methods Mentioned

BETA
urine collection

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.